Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn's Disease: Results From the EVOLVE Study.

23 Data in the literature vary with respect to the rate of SAEs and SIs during treatment with vedolizumab and TNFα inhibitors; however, there is an overall trend of comparable or fewer safety events with vedolizumab. 24 In this study, the IR of SAEs and SIs was significantly lower in the vedolizumab group compared with the adalimumab group, with 36 and 59 events in 25 patients in the vedolizumab and adalimumab groups, respectively.

also in 4,871 other papers